Cheng Y - Search Results

1

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331^☆.

Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M. Spigel DR, et al. Among authors: cheng y. Ann Oncol. 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071. Epub 2021 Feb 1. Ann Oncol. 2021. PMID: 33539946 Free article. Clinical Trial.

2

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.

Biganzoli L, Di Vincenzo E, Jiang Z, Lichinitser M, Shen Z, Delva R, Bogdanova N, Vivanco GL, Chen Z, Cheng Y, Just M, Espié M, Vinholes J, Hamm C, Crivellari D, Chmielowska E, Semiglazov V, Dalenc F, Smith I. Biganzoli L, et al. Among authors: cheng y. Ann Oncol. 2012 Jan;23(1):111-118. doi: 10.1093/annonc/mdr043. Epub 2011 Mar 28. Ann Oncol. 2012. PMID: 21444356 Free article. Clinical Trial.

3

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, Chen ZH, Yan HH, Song Y, Chen JH, Feng WN, Xu CR, Wang Z, Chen HJ, Zhong WZ, Liu YP, Wu YL. Zhou Q, et al. Among authors: cheng y. Ann Oncol. 2014 Dec;25(12):2385-2391. doi: 10.1093/annonc/mdu463. Epub 2014 Oct 3. Ann Oncol. 2014. PMID: 25281710 Free article. Clinical Trial.

4

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MCL, Zhang Y, Xia F, Zuo Y. Wu YL, et al. Among authors: cheng y. Ann Oncol. 2015 Sep;26(9):1883-1889. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23. Ann Oncol. 2015. PMID: 26105600 Free article. Clinical Trial.

5

[Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].

Liu JJ, Zhang S, Wu CJ, Ma LX, Liu Y, Li H, Cui HX, Cheng Y. Liu JJ, et al. Among authors: cheng y. Zhonghua Zhong Liu Za Zhi. 2016 Mar 23;38(3):211-7. doi: 10.3760/cma.j.issn.0253-3766.2016.03.010. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 26988828 Chinese.

6

[Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].

Yang CL, Ma LX, Sun SY, Cui HX, Li ZL, Cheng Y. Yang CL, et al. Among authors: cheng y. Zhonghua Zhong Liu Za Zhi. 2016 Jun 23;38(6):454-9. doi: 10.3760/cma.j.issn.0253-3766.2016.06.010. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27346404 Chinese.

7

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T. Nokihara H, et al. Among authors: cheng y. Ann Oncol. 2017 Nov 1;28(11):2698-2706. doi: 10.1093/annonc/mdx419. Ann Oncol. 2017. PMID: 29045553 Free PMC article. Clinical Trial.

8

Physiological characteristics and related gene expression of after-ripening on seed dormancy release in rice.

Du W, Cheng J, Cheng Y, Wang L, He Y, Wang Z, Zhang H. Du W, et al. Among authors: cheng j, cheng y. Plant Biol (Stuttg). 2015 Nov;17(6):1156-64. doi: 10.1111/plb.12371. Epub 2015 Aug 6. Plant Biol (Stuttg). 2015. PMID: 26205956

9

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study.

Yang LQ, Sun XC, Qin SK, Cheng Y, Shi JH, Chen ZD, Wang QM, Zhang HL, Hu B, Liu B, Zhang QY, Wu Q, Wang D, Shu YQ, Dong J, Han BH, Wang KM, Dang CX, Li JL, Wang HB, Li BL, Lu JG, Zhang ZH, Chen YX. Yang LQ, et al. Among authors: cheng y. Eur J Cancer Care (Engl). 2017 Nov;26(6):e12668. doi: 10.1111/ecc.12668. Epub 2017 Apr 10. Eur J Cancer Care (Engl). 2017. PMID: 28393417 Free PMC article. Clinical Trial.

10

A polymorphism in the DNA repair domain of APEX1 is associated with the radiation-induced pneumonitis risk among lung cancer patients after radiotherapy.

Li H, Liu G, Xia L, Zhou Q, Xiong J, Xian J, Du M, Zhang L, Liao L, Su X, Li Z, Luo Q, Cheng Y, Zhang T, Wang D, Yang ZZ. Li H, et al. Among authors: cheng y. Br J Radiol. 2014 Aug;87(1040):20140093. doi: 10.1259/bjr.20140093. Epub 2014 Jun 2. Br J Radiol. 2014. PMID: 24884729 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27,176 results

Search Page